03 SEP 2010 05:51 LUNG ACCRUAL REPORT - OPEN and recently closed STUDIES
REGS. REGS. REGS. REGS. REGS.
R LAST LAST LAST LAST LAST # of # of
E ACCR. TOTAL 12 6 3 30 7 ACT. CURR
STUDY G ARM GOAL REGS. Month Month Month DAYS DAYS INSTs IRBs
-------------------------------------- - --------------------------------- ----- ----- ----- ----- ----- ----- ----- ----- -----
S0424-Molecular Epidemiology NSCLC 1 1 Questionnaire & Specimen Sub 980 946 36 20 9 2 0 284 125
----- ----- ----- ----- ----- -----
946 36 20 9 2 0
S0635-Bac, Stg IIIB/IV Bev + OSI-774 1 1 OSI-774 and Bevacizumab 88 68 31 11 4 1 1 187 53
----- ----- ----- ----- ----- -----
68 31 11 4 1 1
S0636-Adeno,IIIB/IV,Nsmk,Bev+OSI-774 1 1 OSI-774 and Bevacizumab 88 89 34 17 10 4 1 175 55
----- ----- ----- ----- ----- -----
89 34 17 10 4 1
S0709-NSCLC, Adv, PRO+, OSI-774+-Chemo 1 1 OSI-774 110 4 3 0 0 0 0 137 52
2 Paclitaxel+Carboplatin+OSI-774 4 4 2 1 0 0
----- ----- ----- ----- ----- -----
8 7 2 1 0 0
S0720-NSCLC,Stg I,ERCC1/RRM1 to Adj Tx 1 1 Specimen Submission 60 11 10 6 5 3 2 211 78
2 Adjuvant chemotherapy 28 26 14 4 0 0
----- ----- ----- ----- ----- -----
39 36 20 9 3 2
S0722-Mesothelioma, RAD001 1 1 Everolimus 60 29 10 9 7 4 1 155 46
----- ----- ----- ----- ----- -----
29 10 9 7 4 1
S0802-ESCLC,Topotecan+/-AVE0005,PhII 1 1 AVE0005 + topotecan 190 39 37 24 11 5 1 190 80
2 Topotecan 39 37 22 12 5 0
----- ----- ----- ----- ----- -----
78 74 46 23 10 1
S0819-NSCLC, Adv, Chemo/Bev +/-Cet 1 1 Chemo+/-Bev w/o Cetuximab 1700 98 97 61 25 7 6 289 129
2 Chemo+/-Bev w/ Cetuximab 102 101 56 24 13 3
----- ----- ----- ----- ----- -----
200 198 117 49 20 9
S0905-Mesothem,cediranib+chemo,PhI/II 1 1 Pemetrexed+CDDP+Cediranib 30mg 128 5 5 5 4 2 1 2 3
----- ----- ----- ----- ----- -----
5 5 5 4 2 1
C140503-NSCL, Lobect v Sublobar resect 1 Total Registrations 9 5 3 1 0 0 97 40
----- ----- ----- ----- ----- -----
9 5 3 1 0 0
C30610-SCLC, Thoracic RT 1 Total Registrations 19 7 4 4 0 0 161 78
----- ----- ----- ----- ----- -----
19 7 4 4 0 0
E1505-Stg IB-IIIA chemo +/- Bev 1 Total Registrations 140 53 30 18 8 3 385 202
----- ----- ----- ----- ----- -----
140 53 30 18 8 3
16 rows selected.
no rows selected
03 SEP 2010 05:51 LUNG Recently Closed Studies Accrual Report
O
P REGS. REGS.
E DATE TOTAL LAST LAST
N CLOSED REG. ARM REGS. 30 DAYS 7 DAYS
- ---------- ---- --------------------------------- ------ ------- ------
N 01-Sep-10 1 1 OSI-774 and Bevacizumab 89 4 1
------ ------- ------
89 4 1
1 row selected.
03 SEP 2010 05:51 page 1
LUNG SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES
R
E TOTAL
STUDY G ARM SEGMENT REGS.
-------------------------------------- - --------------------------------- ----------------------------------- -----
S0709-NSCLC, Adv, PRO+, OSI-774+-Chemo 1 1 OSI-774 01: 1 cycle of OSI-774 4
1 OSI-774 02: 1 cycle of OSI-774 2
2 Paclitaxel+Carboplatin+OSI-774 01: 1 cycle of Chemo + OSI-774 4
S0722-Mesothelioma, RAD001 1 1 Everolimus 01: Cycle 1/Mod RECIST 29
1 Everolimus 02: 1 cycle/Mod RECIST 19
1 Everolimus 03: 1 cycle/Mod RECIST 10
1 Everolimus 04: 1 cycle/Mod RECIST 7
1 Everolimus 05: 1 cycle/Mod RECIST 3
1 Everolimus 06: 1 cycle/Mod RECIST 2
1 Everolimus 07: 1 cycle/Mod RECIST 1
1 Everolimus 08: 1 cycle/Mod RECIST 1
1 Everolimus 09: 1 cycle/Mod RECIST 1
1 Everolimus 10: 1 cycle/Mod RECIST 1
S0802-ESCLC,Topotecan+/-AVE0005,PhII 1 1 AVE0005 + topotecan 01: Cycle 1 39
1 AVE0005 + topotecan 02: Cycle 1 18
1 AVE0005 + topotecan 03: Cycle 1 4
1 AVE0005 + topotecan 04: Cycle 1 3
1 AVE0005 + topotecan 05: Cycle 1 2
1 AVE0005 + topotecan 06: Cycle 1 1
1 AVE0005 + topotecan 07: Cycle 1 1
1 AVE0005 + topotecan 08: Cycle 1 1
2 Topotecan 01: Cycle 1 39
2 Topotecan 02: Cycle 1 18
2 Topotecan 03: Cycle 1 3
2 Topotecan 04: Cycle 1 3
2 Topotecan 05: Cycle 1 1
2 Topotecan 06: Cycle 1 1
2 Topotecan 10: Cycle 1 1
S0819-NSCLC, Adv, Chemo/Bev +/-Cet 1 1 Chemo+/-Bev w/o Cetuximab 01: Cycle 1 chemo w/o cetuximab 97
1 Chemo+/-Bev w/o Cetuximab 02: Cycle 2 chemo w/o cetuximab 64
1 Chemo+/-Bev w/o Cetuximab 03: Cycle 3 chemo w/o cetuximab 44
03 SEP 2010 05:51 page 2
LUNG SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES
R
E TOTAL
STUDY G ARM SEGMENT REGS.
-------------------------------------- - --------------------------------- ----------------------------------- -----
S0819-NSCLC, Adv, Chemo/Bev +/-Cet 1 1 Chemo+/-Bev w/o Cetuximab 04: Cycle 4 chemo w/o cetuximab 38
1 Chemo+/-Bev w/o Cetuximab 05: Cycle 5 chemo w/o cetuximab 31
1 Chemo+/-Bev w/o Cetuximab 06: Cycle 6 chemo w/o cetuximab 21
1 Chemo+/-Bev w/o Cetuximab 07: Bevacizumab 7
1 Chemo+/-Bev w/o Cetuximab 08: Bevacizumab 4
1 Chemo+/-Bev w/o Cetuximab 09: Bevacizumab 1
1 Chemo+/-Bev w/o Cetuximab 10: Bevacizumab 1
1 Chemo+/-Bev w/o Cetuximab 11: Bevacizumab 1
2 Chemo+/-Bev w/ Cetuximab 01: Cycle 1 chemo+cetuximab 100
2 Chemo+/-Bev w/ Cetuximab 02: Cycle 2 chemo+cetuximab 61
2 Chemo+/-Bev w/ Cetuximab 03: Cycle 3 chemo+cetuximab 47
2 Chemo+/-Bev w/ Cetuximab 04: Cycle 4 chemo+cetuximab 38
2 Chemo+/-Bev w/ Cetuximab 05: Cycle 5 chemo+cetuximab 24
2 Chemo+/-Bev w/ Cetuximab 06: Cycle 6 chemo+cetuximab 18
2 Chemo+/-Bev w/ Cetuximab 07: Cetuximab +/- Bevacizumab 12
2 Chemo+/-Bev w/ Cetuximab 08: Cetuximab +/- Bevacizumab 10
2 Chemo+/-Bev w/ Cetuximab 09: Cetuximab +/- Bevacizumab 6
2 Chemo+/-Bev w/ Cetuximab 10: Cetuximab +/- Bevacizumab 5
2 Chemo+/-Bev w/ Cetuximab 11: Cetuximab +/- Bevacizumab 4
2 Chemo+/-Bev w/ Cetuximab 12: Cetuximab +/- Bevacizumab 3
2 Chemo+/-Bev w/ Cetuximab 13: Cetuximab +/- Bevacizumab 1
2 Chemo+/-Bev w/ Cetuximab 14: Cetuximab +/- Bevacizumab 1
2 Chemo+/-Bev w/ Cetuximab 15: Cetuximab +/- Bevacizumab 1
S0905-Mesothem,cediranib+chemo,PhI/II 1 1 Pemetrexed+CDDP+Cediranib 30mg 01: Cohort 1, 30mg 5
1 Pemetrexed+CDDP+Cediranib 30mg 02: Cohort 1, 30mg 1
56 rows selected.
SWOG StatCtr Home Page
1 row selected.